SPECIAL NOTICE
99 -- NCI OA Special Notice of Subcontract Opportunity at the Frederick National Laboratory for Cancer Research: Inpatient Treatment with Anti-Coronavirus Immunoglobulin
- Notice Date
- 9/14/2020 12:02:21 PM
- Notice Type
- Special Notice
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- NIH National Cancer Institute Rockville MD 20850 USA
- ZIP Code
- 20850
- Solicitation Number
- S21-089
- Response Due
- 9/16/2020 11:00:00 AM
- Archive Date
- 10/01/2020
- Point of Contact
- Maureen Wilson
- E-Mail Address
-
maureen.wilson2@nih.gov
(maureen.wilson2@nih.gov)
- Description
- Sources Sought Notice in support of the National Institute of Allergy and Infectious Diseases (NIAID) to initiate the management, oversight, and conduct of �An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Hospitalized Patients at Onset of Clinical Progression of COVID-19� THIS IS A SOURCES SOUGHT NOTICE ONLY. THIS IS NOT A REQUEST FOR PROPOSAL. The FNLCR is a Government-Owned Contractor-Operated (GOCO) Federally Funded Research and Development Center (FFRDC) located at Fort Detrick, Maryland. The FNLCR partners with university, government, and corporate scientists to speed the translation of laboratory research into new diagnostic tests and treatments for cancer and AIDS. FNLCR is a multi-program laboratory currently operated by Leidos Biomedical Research Inc. (Leidos Biomed) for the National Cancer Institute (NCI) under Prime Contract No. 75N91019D00024, which provides Operations and Technical Support (OTS) for the Frederick National Lab. The Government assumes no liability for reimbursement for any effort or associated costs to respond, nor for any information provided as a result of this notice as no information is being requested. Please be advised that any submissions provided despite the aforementioned notice that no information is requested become Government property and will not be returned, nor will there be any ensuing discussions or debriefings of any responses. Responses submitted to this notice are not offers and cannot be accepted by the U.S. Government to form a binding contract. It is the responsibility of the interested parties to monitor this site and any sites referenced herein for additional information pertaining to business opportunities with the FNLCR, if any. Description of Work:� ��NIAID has requested the services of Leidos Biomedical Research, Inc. (LBR) to initiate the management, oversight, and conduct of �An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Hospitalized Patients at Onset of Clinical Progression of COVID-19� (short title, Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC)) referred to in this RFI document as ITAC.� This protocol will serve as a platform for assessing treatments for adult patients hospitalized for medical management of COVID-19 without related serious end-organ failure. Trials will involve sites around the world strategically chosen to ensure rapid enrollment. Initially, this trial will compare hIVIG with matched placebo, when added to standard of care (SOC), for preventing further disease progression and mortality related to COVID-19.� SOC will include remdesivir unless it is contraindicated for an individual patient.� In future versions of the protocol, one or more drugs from a different class and with different mechanisms of action may be studied. Such treatments could be studied along with hIVIG if it is found effective and safe in this initial version of the protocol.� Leidos Biomedical Research, Inc.� POC: If you are interested in obtaining the Request for Information, please contact Maureen Wilson, Sr. Subcontracts Administrator at maureen.wilson2@nih.gov �� For information concerning other opportunities with the FNLCR, please refer to: https://frederick.cancer.gov/workwithus/solicitations
- Web Link
-
SAM.gov Permalink
(https://beta.sam.gov/opp/4c668953be1646a3887d22958e0757d1/view)
- Record
- SN05796212-F 20200916/200914230145 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |